Annual Drug Patent Expirations for RYTARY
Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for RYTARY.
This drug has thirty-eight patent family members in fourteen countries.
The generic ingredient in RYTARY is carbidopa; levodopa. One supplier is listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
